期刊文献+

PPARγ激动剂对实验性自身免疫性脑脊髓炎钙激活中性蛋白酶表达的影响 被引量:2

Effects of PPARγ agonist on calpain expression in model of acute experimental autoimmune encephalomyelitis
下载PDF
导出
摘要 目的:探讨过氧化物体增殖剂激活的受体γ激动剂对大鼠实验性自身免疫性脑脊髓炎(EAE)的治疗作用,以及对其脑组织中钙激活的中性蛋白酶(calpain)表达的影响。方法:建立大鼠EAE动物模型,分别给予PPARγ激动剂罗格列酮和非甾体类抗炎药布洛芬预处理,通过各组间临床表现评分评价药物疗效,RT-PCR法检测calpain mRNA的表达,Western blotting法检测calpain蛋白表达水平。结果:罗格列酮和布洛芬治疗组大鼠的临床表现评分显著低于EAE模型组;3组间calpain mRNA表达水平无显著差异(P>0.05),但罗格列酮和布洛芬组calpain蛋白质的表达明显低于EAE模型组(P<0.05)。结论:PPARγ激动剂能够显著减轻EAE大鼠的临床症状,抑制calpain蛋白质的表达,表明PPARγ激动剂对实验性自身免疫性脑脊髓炎大鼠具有脑保护作用。 AIM: To explore the effects of peroxisome proliferator- activated receptor γ (PPARγ) agonist on calcium - activated neutral proteinase, calpain, expression in the brain of rats with acute experimental autoimmune encephalomyelitis (EAE). METHODS : EAE model was established in rats by inoculating the homogenate contained spinal cord of guinea pig and complete Freund's adjuvant. Respectively, the PPARγ agonist rosiglitazone and non - steroid anti - inflammatory drug (NSAID) ibuprofen were used to treat the EAE rats. Outcome measures (Koh's scale) were applied at baseline and after treatment to assess the improvement of clinical symptoms. Calpain expression levels were detected by RT - PCR and Western blotting. RESULTS : All the groups showed significant improvements of scales scores after treatment with rosiglitazone and ibuprofen. No significant difference of the expression of calpain mRNA was found among EAE group, rosiglitazone and ibuprofen groups ( P 〉 0.05 ), but the expression of calpain reduced markedly in rosiglitazone and ibuprofen groups compared with that in EAE group ( P 〈 0. 05 ). CONCLUSION : Rosiglitazone and ibuprofen inhibit the expression of calpain and improve the clinical symptoms of EAE rats. PPARγ agonist plays a neuroprotective role in EAE rats.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2007年第5期955-958,共4页 Chinese Journal of Pathophysiology
基金 重庆市自然科学基金资助项目[No.渝科委计(2001)54号文52]
关键词 罗格列酮 布洛芬 卡配因 脑脊髓炎 实验性自身免疫性 过氧化酶体激增剂活化受体γ Rosiglitazone Ibuprofen Calpain Encephalomyelitis, experimental autoimmune Peroxisome proliferator - activated receptorγ
  • 相关文献

参考文献13

  • 1Duvanel CB,Honegger P,Pershadsingh H,et al.Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro[J].J Neurosci Res,2003,71(2):246 -255.
  • 2Shields DC,Schaecher KE,Saido TC.A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme,calpain[J].Proc Natl Acad Sci USA,1999,96(20):11486 -11491.
  • 3Koh CS,Paterson PY.Suppression of clinical signs of cell-transferred experimental allergic encephalomyelitis and altered cerebrovascular permeability in Lewis rats treated with a plasminogen activator inhibitor[J].Cell Immunol,1987,107(1):52 -63.
  • 4Mohan R,Heyman RA.Orphan nuclear receptor modulators[J].Curr Top Med Chem,2003,3 (14):1637 -1647.
  • 5Polak PE,Kalinin S,Dello RC,et al.Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis[J].J Neuroimmunol,2005,168(1 -2):65-75.
  • 6Mudaliar S,Henry RR.New oral therapies for type 2 diabetes mellitus:the glitazones or insulin sensitizers[J].Annu Rev Med,2001,52(1):239-257.
  • 7Jiang C,Ting AT,Seed B.PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines[J].Nature,1998,391(6662):82 -86.
  • 8Schmidt S,Moric E,Schmidt M.Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T-lymphocytes derived from MS patients[J].J Leukoc Biol,2004,75 (3):475-478.
  • 9Landreth GE,Heneka MT.Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease[J].Neurobiol Aging,2001,22(6):937 -944.
  • 10Barnoy S,Kosower NS.Caspase-1-induced calpastatin degradation in myoblast differentiation and fusion:cross -talk between the caspase and calpain systems[J].FEBS Lett,2003,546(2-3):213-217.

同被引文献25

  • 1Fischer C,Mauguitere F,Ibanez V,et al.The actue deafness of definite multiple sclerosis:BAEP patterns[J].Electroenceph Clin Neurophysiol,1985,61(1):7-15.
  • 2Bergamaschi R,Romani A,Zapooli F,et al.MRI and brainstem auditory evoked potential evidence of eighth cranial nerve involvement in multiple sclerosis[J].Neurology,1997,48(1):270-272.
  • 3Hopf HC,Maurer K.Wave Ⅰ of early auditory evoked potentials in multiple sclerosis[J].Electroencephalogr Clin Neurophysiol,1983,56(1):31-37.
  • 4Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation [J]. J Clin Invest,2006,116(5):1218- 1222.
  • 5Koh CS, Paterson PY. Suppression of clinical signs of cell-transferred experimental allergic encephalomyelitis and altered cerebrovascular permeability in Lewis rats treated with a plasminogen activator inhibitor [ J ]. Cell-Immunol 1987,107 ( 1 ) : 52 - 63.
  • 6Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses[ J]. Annu Rev Immunol, 1998,16:495 - 521.
  • 7Bartosik-Psujek H,Stelmasiak Z. Correlations between IL-4, IL- 12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients [J]. J Neural Transm, 2005,112 (6) :797 - 803.
  • 8Clerici M ,Saresella M ,Trabattoni D, et al. Single-cell a nalysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease [ J ]. J Neuroimmunol,2001,121 ( 1 - 2) :88 - 101.
  • 9Peltoniemi J, Broberg EK, Halenius A, et al. Immunomodulation by roquinimex decreases the expression of IL-23 (P19)mRNA in the brains of herpes simplec virus type 1 infected BALB/c mice [J]. Clin Exp Immunol,2004,137(2):305 -312.
  • 10angrish CI, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell populatkm that induces autoimmune inflammation [ J ]. J Exp Med ,2005,201 (2) :233 - 240.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部